ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?
Mené sur 444 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cet essai de phase II évalue l'efficacité, en fonction de l'expression tumorale de la protéine PD-L1 et du statut des gènes EGFR et ALK, et du point de vue de la proportion de patients ayant obtenu une réponse objective, et la toxicité du durvalumab, un anti-PD-L1, après l'échec de deux lignes de chimiothérapies
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have dramatically expanded the therapeutic armamentarium for non-small-cell lung cancer (NSCLC), and are now standard treatments for patients with advanced disease.1 However, most patients with NSCLC do not respond to PD-1 or PD-L1 inhibitors—an observation motivating ongoing research efforts to identify biomarkers of response. Until now, such efforts have largely centred on assessments of PD-L1 expression, although several other biomarkers are under investigation.
The Lancet Oncology , commentaire, 2017